Q2 FY2026 EarningsQ2 FY26 results were largely in line with revenue expectations at $390.0M vs. $390.1M consensus, but missed significantly on bottom-line GAAP metrics. GAAP Diluted EPS of $0.88 fell well below the $1.23 mean consensus, driven by a surge in SG&A expenses (up 24.1% YoY) including $6.9M in acquisition-related costs. Gross margin improved to 67.9% but remained slightly below the 68.2% consensus. The pending acquisition by Boston Scientific for $374/share remains the primary value anchor for investors.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Penumbra(PEN) the Revenue is 390.05 M (+14.9%), Miss estimate;the EBIT is 41.04 M (+0.52%), Miss estimate;the EPS is 0.88 (-23.48%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.39B14.90%
0.39B14.91%
-0.00B0.01%
EBITMiss expectations
0.04B0.52%
0.06B46.30%
-0.02B45.78%
EPSMiss expectations
0.8823.48%
1.2317.04%
-0.351030.52%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf